No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AMPH240816C45000
- 0.42
- +0.02+5.00%
15min DelayClose Jul 23 15:57 ET
0.48High0.35Low
0.35Open0.40Pre Close14 Volume265 Open Interest45.00Strike Price593.00Turnover41.50%IV12.01%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.42Extrinsic Value100Contract SizeAmericanOptions Type0.1876Delta0.0620Gamma95.41Leverage Ratio-0.0251Theta0.0048Rho17.90Eff Leverage0.0281Vega
Intraday
- 5D
- Daily
News
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock Been Rising: Are Strong Financials Guiding The Market?
Why Amphastar (AMPH) Is Poised to Beat Earnings Estimates Again
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
BofA Securities Maintains Amphastar Pharmaceuticals(AMPH.US) With Hold Rating
Bank of America Securities Reaffirms Their Hold Rating on Amphastar Pharmaceuticals (AMPH)
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Can Manage Its Debt Responsibly
Comments
$Amphastar Pharmaceuticals(AMPH.US$ 📣 Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
✨Bioequivalent and therapeutically equivalent to $TEVA ProAir® HFA Inhalation Aerosol
» ANDA approval
» Indication: Tx or prevention of bronchospasm 🫁
» Product launch in Q3 '24
✨Bioequivalent and therapeutically equivalent to $TEVA ProAir® HFA Inhalation Aerosol
» ANDA approval
» Indication: Tx or prevention of bronchospasm 🫁
» Product launch in Q3 '24
3
The market's growth expectations seem moderated as EPS growth outpaces average annual share price increase. The recent rise in total shareholder return could suggest business improvement over time.
The impressive EPS growth and large insider ownership make Amphastar Pharmaceuticals a potentially attractive investment. The business appears to have reached a growth inflection point.
Insider ownership is moderately high, showing company's interest for all shareholders, but the lack of insider buying and significant selling over the last year, casts some doubt on the company's outlook.
Amphastar Pharmaceuticals experienced a dip, but long-term its performance is strong due to profitability transition and faster EPS growth versus share price. However, market growth expectations are moderated. Share price momentum indicates a potential investment opportunity.
Read more